1. Sweden Stocks

  2. •

    Health technology

  3. •

    Medical specialties
C-Rad AB Class B

C-Rad AB Class B

22.00
SEK
-6.70
(-23.34%)
1.21EPS
29.93P/E
1.20BMarket Cap
Oct 22Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.45
2.61
3.1
3.22
4.5
6.18
6.64
6.66
7.74
8.92
12.57
13.89
13.09
12.94
Basic EPS, GAAP
-1.14
-0.35
-0.99
-1.21
-0.37
0.69
-0.45
0.43
0.74
0.22
1.05
1.67
0.31
1.21
Free Cash Flow per Basic Share
-1.52
-0.92
-1.37
-1.87
-0.17
-0.44
0.38
0.51
0.5
0.25
0.87
0.86
1.86
0.12
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.1
Book Value per Share
1.92
1.87
1.8
2.39
2.32
3.04
2.69
5.94
6.85
7.18
8.05
9.68
10.46
11.11
Tangible Book Value per Share
1.29
0.94
0.55
1.48
1.4
2.17
2.11
5.4
6.34
6.54
7.16
8.79
9.28
9.68
Basic Weighted Avg Shares
18
20
21
26
30
31
31
33
34
34
34
34
34
34
Sales/Revenue/Turnover
45
53
66
83
133
190
205
222
261
301
425
469
442
437
Operating Margin (%)
-45.11
-33.44
-34.49
-36.95
-6.93
1.6
-3.79
9.06
14
7.22
11.73
15.02
13.72
12.21
Depreciation Expense
6
6
6
6
5
7
21
9
10
10
9
10
10
12
Net Income, GAAP
-21
-7
-21
-31
-11
21
-14
14
25
7
36
56
10
41
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
12.31
29.76
65.19
19.12
29.25
34.04
16.9
Profit Margin (%)
-46.62
-13.43
-32.02
-37.76
-8.19
11.15
-6.72
6.48
9.61
2.48
8.37
12.04
2.37
9.37
Working Capital
21
20
13
46
34
37
55
153
195
215
232
288
296
308
LT Debt
12
17
12
12
- -
- -
20
7
6
4
2
9
9
9
Total Equity
38
38
40
71
71
94
83
200
231
243
271
325
347
366
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
9.64
11.38
3.13
13.79
15.75
8.16
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
9.66
11.34
3.15
13.79
18.66
3.2
- -
Return on Common Equity (%)
-77.34
-18.68
-53.95
-56.41
-15.36
25.68
-15.6
10.15
11.65
3.16
13.83
18.94
3.11
- -

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
9
9
9
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
33
33
33
Market Capitalization
1,061
853
1,197

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
438
435
439
Cash, Cash Equivalents & STI
171
135
138
Accounts Receivable, Net
158
187
185
Inventories
46
51
52
Total Current Liabilities
142
140
131
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
29.64%
11.83%
6.85%
Free Cash Flow
31.56%
61.26%
114.63%
Net Income, GAAP
-32.42%
71.4%
-81.47%
Sales/Revenue/Turnover
22.35%
15.76%
-5.78%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
118
129
100
122
469
2025
119
105
- -
106
442
2026
105
122
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.48
0.31
0.45
0.43
1.67
2025
-0.24
0.12
- -
0.05
0.31
2026
0.33
0.72
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
0.1
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Tomas Blomquist
Full Time Employees
110
Sector
Health technology
Industry
Medical specialties
Address
Sjukhusvägen 12K Uppsala UP Sweden 753 09
IPO Date
May 21, 2007
Website
c-rad.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
C-Rad AB (publ) develops, manufactures and markets surface guided radiation therapy (SGRT) systems and related solutions to enhance precision, safety and efficiency in cancer radiotherapy treatments worldwide. The company's core products include the Catalyst+ HD platform for high-precision patient positioning, intra-fraction motion management and respiratory gating in stereotactic and conventional treatments; Catalyst+ for patient setup, breath-hold reproducibility and online tracking; Catalyst+ PT tailored for particle and proton therapy; Catalyst+ HD Ring Gantry for non-coplanar deliveries; Sentinel 4DCT laser-based optical surface scanning system for positioning and monitoring; cAutoVerify automation software for imaging and accessory validation; cAccessory for treatment accessory registration; and supporting tools such as SmartPhantom RT motorized laser alignment devices, StaticPhantom for laser verification, and high-impact technology (HIT) patient positioning lasers including HIT5, HIT3 and HIT1 models; alongside comprehensive services encompassing installation, maintenance, software upgrades and training. Founded in 2004 and headquartered in Uppsala, Sweden, C-Rad AB operates as the parent of the C-Rad group through subsidiaries including C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, with sales offices and support in the United States, Germany, France, China, Australia, New Zealand and distributors across Europe, Asia-Pacific, Latin America and other regions serving radiation oncology clinics and hospitals. Recent developments encompass new product enhancements unveiled at ESTRO 2025 including an entry-level SGRT solution upgradable to Catalyst+ HD and ergonomic workflow improvements; a strategic partnership with iRT Systems GmbH to advance radiotherapy safety through integrated surface-guided positioning and real-time beam monitoring; leadership changes with Linda Frölén appointed as permanent CFO in June 2024 succeeding interim CFO Jonas Reinhammar; a major 10 MSEK order win for Latin American expansion in Mexico in October 2024; medium-term financial targets announced in May 2025 alongside a solid Q1 2025 interim report reflecting order intake recovery and growth in EMEA and Americas; ongoing collaborations with vendors such as RaySearch Laboratories, Mevion Medical Systems and historical partners Elekta and Varian; and showcase of industry-leading partnerships plus advanced SGRT at ASTRO 2024.